Results 61 to 70 of about 809 (101)

2024 ACVIM Forum Research Abstract Program

Journal of Veterinary Internal Medicine, Volume 38, Issue 5, Page 2840-2970, September/October 2024.
wiley   +1 more source

EIDD-2801 to EIDD-1931 Equimolar Dose Conversion: Derivation and Peer-Reviewed Basis of the 1.27 Molar Weight Ratio

This technical note provides a transparent, source-referenced derivation of the molar weight conversion factor (1.27) used to calculate equimolar doses of EIDD-1931 (N4-hydroxycytidine, NHC) from established EIDD-2801 (molnupiravir) dosing schedules. The factor is a standard stoichiometric ratio derived from the confirmed molecular weights of EIDD-2801
openaire   +2 more sources

In vitro and in vivo efficacy of Molnupiravir against Zika virus infections. [PDF]

Virol Sin, 2023
Wang Z, Yang S, Dai Q, Guo X, Li Y, Li W, Yang X, Yang J, Yan X, Tao H, Luo C, Li S, Chen X, Cao R, Zhong W.   +14 more
europepmc   +1 more source

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters. [PDF]

Int J Mol Sci, 2023
Bakos É, Temesszentandrási-Ambrus C, Özvegy-Laczka C, Gáborik Z, Sarkadi B, Telbisz Á.   +5 more
europepmc   +1 more source

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. [PDF]

Front Pharmacol, 2022
Abdelnabi R, Maes P, de Jonghe S, Weynand B, Neyts J.   +4 more
europepmc   +1 more source

Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine. [PDF]

Nucleic Acids Res, 2023
Xu Z, Flensburg C, Bilardi RA, Majewski IJ.   +3 more
europepmc   +1 more source

Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses. [PDF]

Pharmaceuticals (Basel), 2023
Darnotuk ES, Siniavin AE, Shastina NS, Luyksaar SI, Inshakova AM, Bondareva NE, Zolotov SA, Lubenec NL, Sheremet AB, Logunov DY, Zigangirova NA, Gushchin VA, Gintsburg AL.   +12 more
europepmc   +1 more source

Molnupiravir and Its Antiviral Activity Against COVID-19. [PDF]

Front Immunol, 2022
Tian L, Pang Z, Li M, Lou F, An X, Zhu S, Song L, Tong Y, Fan H, Fan J.   +9 more
europepmc   +1 more source

SARS-CoV-2 infection induces pro-fibrotic and pro-thrombotic foam cell formation. [PDF]

Nat Microbiol
Battaglia DM, Post CE, Yao W, Wahl A, Gralinski LE, Liu H, Dang H, Madden VJ, White KK, Leist SR, Dinnion KH, De la Cruz G, Midkiff BR, Froggatt HM, Gully K, Zweigart M, Reader JR, Olstad KJ, Everitt JI, Van Rompay KKA, De Paris K, Sajti E, Pickles RJ, Browne EP, Jones CD, Boucher RC, Baric RS, Garcia JV.   +27 more
europepmc   +1 more source

Development of a stable replicon system of a pangolin merbecovirus for antiviral screening. [PDF]

Virol Sin
Wu CG, Wang JH, Zhu B, Chen J.
europepmc   +1 more source